ArticleClinical and translational science2023

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.

Erik Hahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.